Loading patent…
AssigneeNeoRx Corporation
InventorsDavid J. Grainger, James C. Metcalfe, Peter L. Weissberg
Estimating the term…
TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.
A therapeutic method to treat procedural vascular trauma, comprising orally administering to a mammal subjected to the vascular trauma an amount of an agent effective upon oral administration to elevate the level of TGF-beta so as to inhibit the pathological proliferation of vascular smooth muscle cells.
A method for reducing or inhibiting restenosis associated with an angioplasty procedure, which method comprises orally administering to a mammal an amount of an agent effective upon oral administration to elevate levels of TGF-beta.
Dependencies are inferred from the claim text.